hotspot -WSS

hotspot

author：comprehensive 2025-10-01 17:19:52 - browse：84

Chemotherapy infusion — The White House outlined its efforts to end shortages of three key generic chemotherapies. But experts want more more details. Gerry Broome/AP

WASHINGTON — The White House says it’s working to end shortages of three key generic chemotherapies. But experts said the administration would have to provide more details to fully mitigate the health care system’s concerns.

Carboplatin, cisplatin, and methotrexate are three of 15 cancer drugs in shortage in the United States. They have been staples of cancer treatment for decades, according to a White House blog post, but their supply in the United States has been nearly halved in the past year. The shortages have forced doctors to ration the drugs and alter treatment plans, leaving cancer patients to wonder whether their survival odds are hurt.

In its blog post, the White House noted that it’s now allowing Chinese imports of cisplatin. The Food and Drug Administration is also working with generic drug companies to boost production of all three drugs, but it didn’t say which companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Micronoma's microbiome cancer diagnostic approach under fire

WSS

What to make of Biden’s latest efforts on cancer research

Pig kidney works a record two months in donated body

New weight loss drugs vying to be the next Wegovy or Mounjaro

Regeneron agrees to White House price limits on anti

Adults seen as increasingly susceptible to measles

Pig kidney works a record two months in donated body

explore

hotspot

focus

New air purifier tech could be key to improving indoor air quality

Will the IRA bring competition to the biologics market?

Medicare details structure of new drug price negotiation program

Wildfire pollution widens asthma inequities on Long Island

Continuity nursing helped my family in our darkest PICU moments

New weight loss drugs vying to be the next Wegovy or Mounjaro

ChatGPT in medicine: STAT answers readers' burning questions

FDA panel endorses Alnylam’s heart drug — after picking it apart

Heart attack and stroke risk calculators need revising

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

hotspot

What to expect as Trump is arraigned on his Jan 6. indictment

What the airline industry can learn from medicine

EQRx, failed developer of low

Mitch McConnell episode has important public health takeaway

EQRx, failed developer of low

Food makers to regulators: Ultra

Wikipedia

focus

hotspot

hotspot